L

LTR Pharma Ltd
ASX:LTP

Watchlist Manager
LTR Pharma Ltd
ASX:LTP
Watchlist
Price: 0.725 AUD -4.61% Market Closed
Market Cap: 111.5m AUD
Have any thoughts about
LTR Pharma Ltd?
Write Note

Net Margin
LTR Pharma Ltd

-14 192.8%
Current
-6 376%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-14 192.8%
=
Net Income
-7m
/
Revenue
49k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
AU
LTR Pharma Ltd
ASX:LTP
101.1m AUD
-14 193%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-79%
US
Eli Lilly and Co
NYSE:LLY
747.7B USD
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
35%
US
Johnson & Johnson
NYSE:JNJ
342.5B USD
17%
US
Merck & Co Inc
NYSE:MRK
252.8B USD
19%
CH
Roche Holding AG
SIX:ROG
216.7B CHF
20%
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP
13%
CH
Novartis AG
SIX:NOVN
179.3B CHF
35%
US
Pfizer Inc
NYSE:PFE
152.2B USD
7%
Country AU
Market Cap 101.1m AUD
Net Margin
-14 193%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 747.7B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.8T DKK
Net Margin
35%
Country US
Market Cap 342.5B USD
Net Margin
17%
Country US
Market Cap 252.8B USD
Net Margin
19%
Country CH
Market Cap 216.7B CHF
Net Margin
20%
Country UK
Market Cap 170.3B GBP
Net Margin
13%
Country CH
Market Cap 179.3B CHF
Net Margin
35%
Country US
Market Cap 152.2B USD
Net Margin
7%
No Stocks Found

LTR Pharma Ltd
Glance View

Market Cap
101.1m AUD
Industry
Pharmaceuticals

LTR Pharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The firm is focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction.

LTP Intrinsic Value
0.008 AUD
Overvaluation 99%
Intrinsic Value
Price
L
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-14 192.8%
=
Net Income
-7m
/
Revenue
49k
What is the Net Margin of LTR Pharma Ltd?

Based on LTR Pharma Ltd's most recent financial statements, the company has Net Margin of -14 192.8%.